The decrease in T<sub>SCM</sub> and T<sub>CM</sub> together with the increase in differentiated T<sub>EM</sub> and T<sub>EF</sub> subsets in CD8+ T cells may explain the reduced T cell response and subdued anti-leukemia capacity in AML patients. This evidence concerns the gene CD8A and acute myeloid leukemia.